Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the election of Kathleen Tregoning to...
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the Jefferies...
Compass Pathways (NASDAQ:CMPS) executives said the company remains on track to target a fourth-quarter New Drug Application filing for COMP360, its synthetic psilocybin treatment candidate for treatment-resistant...
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the RBC...
Compass Pathways (NASDAQ:CMPS) said it has begun a rolling New Drug Application submission for COMP360, its investigational psilocybin treatment for treatment-resistant depression, and is preparing for...
FDA granted Compass NDA rolling submission and review request, based on strength of Phase 3 data CNPV awarded for COMP360 in TRD, further accelerating...
Barchart Research What to Expect from CMPS Earnings CMPS Generated May 12, 2026 Current Price $9.37 EPS Estimate $$-0.45 Consensus Rating Strong Buy Average Move 8.00% Can Compass Pathways Justify Its...
Compass management will host a conference call at 8:00 am ET (1:00 pm UK)Â
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under...
Trump signed an order to accelerate the regulatory progression of psychedelic therapies. Can Compass Pathways make use of it?